Lantus Solostar

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a solution for subcutaneous injection (pre‑filled pen) for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams across multiple continents worldwide, ensuring consistent quality, regulatory compliance and adherence to EU pharmacopeia standards.

Insulin glargine is a basal insulin analog used to manage blood glucose in diabetes.

- Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels. - Type 2 diabetes mellitus: complements mealtime insulin or oral agents to achieve overall glycemic control. - Patients requiring basal insulin therapy: offers a steady, peak‑free insulin level for up to 24 hours.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight with chronic use. - Edema: mild fluid retention, often in the lower extremities. - Lipodystrophy: localized changes in fat tissue at injection sites. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycemia: can lead to loss of consciousness or seizures. - Anaphylactic reaction: rare but potentially life‑threatening allergic response. - Hypokalemia: low potassium levels, especially with high insulin doses. - Severe edema: significant fluid accumulation requiring medical attention. - Insulin antibodies: formation of antibodies that may alter insulin action. - Angio‑edema: swelling of deeper skin layers, potentially affecting airway.

When using Lantus Solostar, consider the following precautions: - Dose titration: adjust based on fasting glucose and HbA1c under medical supervision. - Hypoglycemia risk: monitor blood glucose regularly to detect low levels early. - Renal impairment: use caution; reduced kidney function may require dose modification. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin glargine may interact with several medications.

Major Interactions (Avoid): - Concurrent sulfonylureas: increased risk of severe hypoglycemia. - Beta‑blockers: may mask typical hypoglycemia symptoms. - Systemic corticosteroids: can diminish insulin effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose review. - Thiazide diuretics: can raise blood glucose levels. - Alcohol: may cause unpredictable fluctuations in glucose control.